top of page

Subscribe to Our Newsletter

Thanks for submitting!

FDA Requirements on Filters for Injectable Drug Products

According to Section 211.72 of Part 211, filters employed in the liquid filtration process for injectable drug products must adhere to specific guidelines. The primary objective is to ensure that filters do not release fibers into the final drug products. Fiber-releasing filters are generally prohibited; however, in certain cases where their use is unavoidable, additional measures must be taken to minimize potential risks.

Fiber-Releasing Filters and Additional Safeguards

While the ideal scenario is to manufacture injectable drug products without the use of fiber-releasing filters, there may be instances where their inclusion becomes necessary. In such cases, manufacturers must implement supplementary precautions to maintain product integrity. One such measure is the subsequent use of a nonfiber-releasing filter with a maximum nominal pore size rating of 0.2 micron. However, if specific manufacturing conditions dictate, a slightly larger maximum nominal pore size rating of 0.45 micron is acceptable.

Mitigating Particle Content

The inclusion of an additional nonfiber-releasing filter aims to minimize the content of particles in the injectable drug product. By implementing this second filtration step, manufacturers ensure that any particles introduced by the initial fiber-releasing filter are effectively reduced. This process aids in maintaining the desired level of product purity and minimizing the potential impact on patient safety.

Prohibition of Asbestos-Containing Filters

It is crucial to note that the use of filters containing asbestos is strictly prohibited under this regulation. Asbestos, a hazardous material known for its carcinogenic properties, poses significant health risks. Thus, manufacturers must be vigilant in their compliance with this prohibition to safeguard both the product and the individuals involved in its production, administration, and use.

Ensuring Regulatory Compliance

The FDA's stringent regulations exist to protect consumers and ensure the quality and safety of pharmaceutical products. Manufacturers operating within the pharmaceutical industry must adhere to these guidelines meticulously. Compliance with Part 211, Subpart D of Title 21 is of utmost importance when it comes to the selection and use of filters in the manufacturing process of injectable drug products. By following the prescribed requirements and implementing the necessary precautions, manufacturers can maintain the highest standards of quality, thereby ensuring the safety and well-being of patients who rely on these vital medications.

Contact BioBoston Consulting now or visit our website to learn more about how we can support your regulatory activities.

7 views0 comments
bottom of page